Prelude Therapeutics Incorporated (PRLD)
| Market Cap | 377.87M +406.4% |
| Revenue (ttm) | 16.72M +138.9% |
| Net Income | -77.80M |
| EPS | -0.99 |
| Shares Out | 99.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 220,938 |
| Open | 4.050 |
| Previous Close | 4.080 |
| Day's Range | 3.742 - 4.060 |
| 52-Week Range | 0.750 - 5.540 |
| Beta | 1.01 |
| Analysts | Strong Buy |
| Price Target | 8.00 (+109.97%) |
| Earnings Date | May 12, 2026 |
About PRLD
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCel... [Read more]
Financial Performance
In 2025, Prelude Therapeutics's revenue was $12.14 million, an increase of 73.43% compared to the previous year's $7.00 million. Losses were -$99.50 million, -21.76% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for PRLD stock is "Strong Buy." The 12-month stock price target is $8.0, which is an increase of 109.97% from the latest price.
News
Prelude Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
The company presented a robust precision oncology pipeline, including a selective JAK2 V617F inhibitor in phase I, a KAT6A degrader for ER+ breast cancer, and a CALR-targeted antibody-degrader conjugate. Each program is designed for improved efficacy and safety, with multiple data catalysts expected in the next 12–24 months.
Prelude Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
Goldman Sachs analyst Corinne Johnson initiated coverage of Prelude Therapeutics (PRLD) with an Early-Stage Biotech rating. The firm says the company’s “differentiated approach” in metastatic breast c...
Prelude Therapeutics reports Q1 EPS (13c), consensus (27c)
“Through this first quarter of 2026, our company has continued to demonstrate focused execution of the strategic priorities we set forth late last year.” stated Kris Vaddi, Chief Executive Officer…
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF)
Prelude Therapeutics Earnings release: Q1 2026
Prelude Therapeutics released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Prelude Therapeutics Quarterly report: Q1 2026
Prelude Therapeutics has published its Q1 2026 quarterly earnings report on May 12, 2026.
Prelude Therapeutics Slides: Corporate presentation
Prelude Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 11, 2026.
Prelude Therapeutics initiated with a Buy at D. Boral Capital
D. Boral Capital initiated coverage of Prelude Therapeutics (PRLD) with a Buy rating and $9 price target Prelude is a clinical-stage oncology company advancing a precision medicine approach through a…
Prelude Therapeutics Proxy statement: Proxy filing
Prelude Therapeutics filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Prelude Therapeutics Proxy statement: Proxy filing
Prelude Therapeutics filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Prelude Therapeutics price target raised to $8 from $5 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Prelude Therapeutics (PRLD) to $8 from $5 and keeps a Buy rating on the shares after the company presented preclinical data on…
Prelude Therapeutics Slides: Corporate presentation
Prelude Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on April 20, 2026.
Prelude Therapeutics presents new preclinical data from PRT13722 study
Prelude Therapeutics (PRLD) announced the presentation of new preclinical data from its lead development candidate, PRT13722. PRT13722 is being developed for the treatment of hormone receptor positive...
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced the pri...
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
Data Demonstrate Potential for Differentiated Efficacy and Safety Profile, Including Complete Responses as Monotherapy in Multiple CDX and PDX Models of HR+/HER2- Breast Cancer
Prelude Therapeutics announces Charles Morris as chief medical officer
Prelude Therapeutics (PRLD) announced that Charles Morris will join the company as chief medical officer effective, April 20. Most recently, he served as Chief Medical Officer at Lava Therapeutics. Pu...
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer
WILMINGTON, Del., April 15, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude Therapeutics” or the “Company”), a clinical-stage precision oncology company, today anno...
Prelude Therapeutics management to meet with Citizens
Meeting to be held in Boston on March 25 hosted by Citizens.
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
WILMINGTON, Del., March 17, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that a poster with preclinical data on the Company'...
Prelude Therapeutics price target raised to $6 from $3 at Citizens
Citizens raised the firm’s price target on Prelude Therapeutics (PRLD) to $6 from $3 and keeps an Outperform rating on the shares following the Q4 report. The preclinical JAK2V617F data…
Prelude Therapeutics Transcript: Conference
The company has shifted its focus to JAK2V617F and KAT6A programs, targeting clinical entry in 2026, and is advancing a novel CALR degrader. Mutant-selective approaches and strategic partnerships, including a deal with Incyte, support a strong financial runway into 2027.
Prelude Therapeutics Annual report: Q4 2025
Prelude Therapeutics has published its Q4 2025 annual report on March 10, 2026.
Prelude Therapeutics Earnings release: Q4 2025
Prelude Therapeutics released its Q4 2025 earnings on March 10, 2026, summarizing the period's financial results.
Prelude Therapeutics reports FY25 EPS ($1.29) vs. ($1.68) last year
“Since the announcement of our strategic shift in November of 2025, our team continues to operate with a clear focus on steady execution on our JAK2V617F inhibitor and KAT6 degrader…
Prelude Therapeutics sees cash runway into 2Q27
Cash, cash equivalents, restricted cash and marketable securities as of December 31, 2025 were $106.4 million. The Company anticipates that its existing cash, cash equivalents and marketable securitie...